Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial

被引：0

作者：

Sharma, A. ^{[1
]}

Inzucchi, S. E. ^{[2
]}

Testani, J. ^{[3
]}

Ofstad, A. P. ^{[4
]}

Fitchett, D. ^{[5
]}

Mattheus, M. ^{[6
]}

Verma, S. ^{[7
]}

Zannad, F. ^{[8
]}

Wanner, C. ^{[9
]}

Kraus, B. J. ^{[10
]}

机构：

[1] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA

[4] Boehringer Ingelheim Norway KS, Asker, Norway

[5] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[7] Univ Toronto, St Michaels Hosp, Div Cardiac Surg, Toronto, ON, Canada

[8] Univ Lorraine, CHRU Nancy, Ctr Invest Clin Plurithemat 1433, INSERM 1116,FCRIN,INI,CRCT, Nancy, France

[9] Univ Hosp Wurzburg, Dept Internal Med 1, Wurzburg, Germany

[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2021年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：175 / 175

页数：1

共 50 条

[31] EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL
Ruggenenti, Piero
Inzucchi, Silvio
Zinman, Bernard
Hantel, Stefan
Koitka-Weber, Audrey
von Eynatten, Maximilian
Wanner, Christoph
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 487 - 487
[32] Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial
Hadjadj, Samy
Cooper, Mark E.
Steubl, Dominik
Petrini, Michaela
Hantel, Stefan
Mattheus, Michaela
Wanner, Christoph
Thomas, Merlin C.
KIDNEY MEDICINE, 2024, 6 (03)
[33] Empagliflozin and progression of chronic kidney disease in type 2 diabetes complicated by nephrotic-range proteinuria: insights from the EMPA-REG OUTCOME trial
Ruggenenti, P.
Inzucchi, S.
Zinman, B.
Hantel, S.
Koitka-Weber, A.
von Eynatten, M.
Wanner, C.
DIABETOLOGIA, 2018, 61 : S508 - S508
[34] Relationship between hypoglycaemia, cardiovascular outcomes, and empagilflozin treatment in the EMPA-REG OUTCOME® trial
Fitchett, David
Inzucchi, Silvio E.
Wanner, Christoph
Mattheus, Michaela
George, Jyothis T.
Vedin, Ola
Zinman, Bernard
Johansen, Odd Erik
EUROPEAN HEART JOURNAL, 2020, 41 (02) : 209 - 217
[35] Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
Perkovic, Vlado
Koitka-Weber, Audrey
Cooper, Mark E.
Schernthaner, Guntram
Pfarr, Egon
Woerle, Hans J.
von Eynatten, Maximilian
Wanner, Christoph
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (12) : 2103 - 2111
[36] Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?
Bajaj, Harpreet Singh
Zinman, Bernard
CANADIAN JOURNAL OF DIABETES, 2016, 40 (05) : 379 - 381
[37] Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
Udell, J.
Zinman, B.
Wanner, C.
Von Eynatten, M.
George, J. T.
Zwiener, I.
Lund, S. S.
Hantel, S.
Fitchett, D.
EUROPEAN HEART JOURNAL, 2019, 40 : 55 - 55
[38] Empagliflozin and cardiorenal outcomes in patients with non-proteinuric kidney disease in the EMPA-REG OUTCOME trial
Wanner, C.
Zinman, B.
George, J. T.
Mattheus, M.
von Eynatten, M.
Inzucchi, S. E.
Hauske, S. J.
DIABETOLOGIA, 2019, 62 : S5 - S5
[39] Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME
Fisher, Miles
BRITISH JOURNAL OF DIABETES, 2020, 20 (02): : 138 - 141
[40] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD): post hoc analyses of the EMPA-REG OUTCOME trial
Ferreira, J. P.
Verma, S.
David, F.
Ofstad, A. P.
Lauer, S.
Zwiener, I.
George, J. T.
Wanner, C.
Zinman, B.
Inzucchi, S. E.
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S450 - S451

← 1 2 3 4 5 →